Compare GSK plc (GSK) vs NRG Energy Inc (NRG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs NRG Energy Inc — how do they compare? GSK plc trades at $46.52 (market cap $91.88B), while NRG Energy Inc trades at $107.73 (market cap $22.35B). The key difference: GSK plc is far larger — about 4.1× NRG Energy Inc's market cap, and GSK plc pays the higher dividend (3.9%). Which is the better fit depends on your goals — on Pluang, investors hold GSK plc for 93 Days and NRG Energy Inc for 63 Days on average.
| GSK | NRG | |
|---|---|---|
Market Cap | $91.88B | $22.35B |
Volume | 7,730,529 | 5,011,942 |
Sector | Health | Utilities |
52-Week High | $61.18 | $184.03 |
52-Week Low | $43.24 | $95.23 |
Typical Hold Time | 93 Days | 63 Days |
Enterprise Value | $111.88B | $46.30B |
Dividend Yield | 3.9% | 1.79% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $46.50, down 1.11% with bearish technical signals, though RSI levels suggest potential oversold conditions. Fundamentally, the company shows strong profitability with 72.73% gross margins and consistent earnings beats, while maintaining a reasonable P/E of 14.89. Recent developments include strategic oncology partnerships and a $750M cancer therapy acquisition, positioning for long-term growth despite facing an HIV patent cliff.
GSK presents a mixed investment case with strong fundamentals and pipeline growth offset by technical weakness and patent expiration risks. The company's £40B sales target and cost-saving initiatives provide upside potential, while analyst consensus leans cautious with 55% hold ratings. Key risks include execution of pipeline development and competitive pressures in core markets.
NRG Energy trades at $107.97, down 0.59% on the day, with a mixed technical picture showing bullish moving averages but neutral oscillators. The company reported Q2 2026 earnings of $1.49 per share, missing expectations of $1.69, though revenue growth remains positive with 2026 projections at $33.1 billion. Recent developments include a landmark 1.2 GW Texas data center power project and the acquisition of LS Power assets, positioning for growth in hyperscale computing demand.
The investment outlook is cautiously optimistic with strong analyst support (70% buy ratings) and a consensus price target of $202.90 offering significant upside. However, recent earnings misses, rising debt levels (56.42% debt-to-asset ratio in 2025), and execution risks on major capital projects present near-term challenges. The stock's valuation appears reasonable with P/E of 27.69 and P/S of 0.65 relative to sector peers.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About NRG Energy Inc
NRG Energy is one of the largest retail energy providers in the U.S., with 7 million customers, including its 2021 acquisition of Direct Energy. It also is one of the largest U.S. independent power producers, with 16 gigawatts of nuclear, coal, gas, and oil power generation capacity primarily in Texas. Since 2018, NRG has divested its 47% stake in NRG Yield, among other renewable energy and conventional generation investments. NRG exited Chapter 11 bankruptcy as a stand-alone entity in December 2003.
Read more on NRG →
